Imaging studies for drugs for the Central Nervous System (CNS) often have the benefit of a less complex workflow than those for oncology trials, but with more advanced scanning and complex quantitative assessments, their analysis can be much more difficult.

To meet the demands of this complexity for CNS trials, WorldCare Clinical delivers in-house, volumetric assessments and other complex longitudinal assessments. Having advanced 3D imaging expertise and subspecialty readers with skill sets over multiple modalities, WCC provides a wealth of radiological excellence across a range of neurological indications. Furthering WCC’s capabilities, we leverage our relationship with the world-class MGH neuroradiology team to provide detailed radiology review for MS trials, Alzheimer’s, and more.

For Alzheimer’s, WCC has recently launched its full-service diagnostic assessment program for Alzheimer’s disease.  This program is based on the model developed by the Alzheimer’s Disease Neuroimaging Initiative (ADNI).  In collaboration with physicists, neuroradiologists and clinicians, WCC can provide a comprehensive evaluation of patients from eligibility review through endpoint assessment.  In addition the longitudinal evaluation of on-study imaging can include qualitative and quantitative analysis of PET-FDG, SPECT-perfusion, PET-Amyloid imaging and cortical atrophy as determined by MRI.

And thanks to the flexible WorldPRO technology, we can perform all trial assessments within a single platform. WCC uses WorldPRO to support remote reading teams, access large reading teams for significant volumes, and ensure reader consistency via training, testing and performance monitoring for advanced modalities.

No matter the size or science, WCC provides the necessary expertise for CNS imaging trials.